Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Buy” by Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned an average rating of “Buy” from the fourteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $12.7692.

TSHA has been the subject of a number of research reports. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Canaccord Genuity Group lifted their target price on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th. BMO Capital Markets lifted their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Finally, Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research report on Tuesday, June 23rd.

Taysha Gene Therapies Trading Up 3.0%

TSHA opened at $5.83 on Friday. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $1.68 billion, a PE ratio of -15.34 and a beta of 1.17. Taysha Gene Therapies has a 1-year low of $2.53 and a 1-year high of $7.30. The firm has a 50-day moving average price of $5.98 and a two-hundred day moving average price of $5.36.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, equities analysts anticipate that Taysha Gene Therapies will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the completion of the sale, the insider directly owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. The trade was a 17.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. raised its stake in shares of Taysha Gene Therapies by 32.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 519,120 shares of the company’s stock worth $3,535,000 after buying an additional 127,644 shares during the last quarter. Militia Capital Management LLC bought a new position in Taysha Gene Therapies in the first quarter valued at approximately $208,000. Seven Fleet Capital Management LP boosted its stake in Taysha Gene Therapies by 274.2% in the first quarter. Seven Fleet Capital Management LP now owns 625,708 shares of the company’s stock valued at $2,797,000 after acquiring an additional 458,485 shares during the last quarter. Bank of America Corp DE grew its holdings in Taysha Gene Therapies by 45.5% during the 1st quarter. Bank of America Corp DE now owns 1,677,046 shares of the company’s stock worth $7,496,000 after acquiring an additional 524,366 shares during the period. Finally, ADAR1 Capital Management LLC grew its holdings in Taysha Gene Therapies by 19.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock worth $13,318,000 after acquiring an additional 483,620 shares during the period. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.